DS-7300
Phase 2
Daiichi SankyoDS-7300 is one of 53 therapeutic programs targeting Non-Small Cell Lung Carcinoma. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
52
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
80 competitors in Non-Small Cell Lung Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Abraxane
Bristol-Myers SquibbPhase 3
Dostarlimab
IncytePhase 3
Alecensa
RochePhase 3
Plavix
SanofiPhase 3
Paraplatin
AAvyxa
Phase 3
DATROWAY
Daiichi SankyoPhase 3
Cabometyx
Bristol-Myers SquibbPhase 3
Alimta
EEagle Vision Pharmaceutical Corp.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for DS-7300. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company